Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis [0.03%]
成人慢性偏头痛药物治疗临床有效性的系统评价和网络 meta 分析
Seyran Naghdi,Martin Underwood,Jason Madan et al.
Seyran Naghdi et al.
Background: Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective. We present a netwo...
Mapping brain functional networks topological characteristics in new daily persistent headache: a magnetoencephalography study [0.03%]
新的持续性日常头痛的脑功能网络拓扑特征：一种脑磁图研究
Dong Qiu,Zhaoli Ge,Yanliang Mei et al.
Dong Qiu et al.
Background: The brain functional network topology in new daily persistent headache (NDPH) is not well understood. In this study, we aim to assess the cortical functional network topological characteristics of NDPH using n...
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? [0.03%]
CGRP受体单克隆抗体治疗无应答者何去何从：转换另一种CGRP受体抗体还是转而使用 gepant类药物？
Marta Waliszewska-Prosół,Doga Vuralli,Paolo Martelletti
Marta Waliszewska-Prosół
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will a...
Hema Mistry,Seyran Naghdi,Martin Underwood et al.
Hema Mistry et al.
Background: Migraine is the world's second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for H...
Translation, cross-cultural adaptation and measurement proprieties of the German version of the Allodynia Symptom Checklist (ASC-12) [0.03%]
German版本的Allodynia症状检查表(ASC-12)的翻译，跨文化适应和测量属性
Tetiana Marusich,Tibor M Szikszay,Anne Sennholz et al.
Tetiana Marusich et al.
Background: Cutaneous allodynia is highly prevalent among migraineurs and is associated with a poor prognosis. The Allodynia Symptom Checklist (ASC-12) is a comprehensive questionnaire to identify the presence and severit...
Ki-Woong Nam,Sungyeon Ha,Min-Jeong Oh et al.
Ki-Woong Nam et al.
Background: Primary headache disorder is a known risk factor for stroke in women and usually improves during the first trimester of pregnancy. However, despite this, some women develop headaches during pregnancy (G-HA), a...
Trends in migraine incidence among women of childbearing age from 1990 to 2019 and the prediction for 2030: an analysis of national data in China [0.03%]
中国育龄女性偏头痛患病率的变化趋势（1990-2019）及2030年的预测：对中国全国性数据的分析
Zhuanzhuan Fan,Jian Kang,Wenting Li et al.
Zhuanzhuan Fan et al.
Background: Migraine is a primary headache, which has been producing heavy disease burden globally. There is no data on the incidence of migraine among women of childbearing age worldwide, including China. This study aime...
Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry [0.03%]
Galcanezumab未纳入临床试验的偏头痛患者的长期疗效和耐受性：来自Galca-only登记处的1055例患者1年随访的现实证据
Victor Obach,Fernando Velasco,Rocio Alvarez Escudero et al.
Victor Obach et al.
Background: Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population ob...
Multicenter Study
The journal of headache and pain. 2023 Nov 22;24(1):157. DOI:10.1186/s10194-023-01690-2 2023
Correction: Global, regional, and national epidemiology of migraine and tension-type headache in youths and young adults aged 15-39 years from 1990 to 2019: findings from the global burden of disease study 2019 [0.03%]
纠正：从1990年到2019年的全球、区域和国家范围内15-39岁人群的偏头痛及紧张性头痛流行病学：来自2019年全球疾病负担研究的发现
Xin-Yu Li,Cheng-Hao Yang,Jia-Jie Lv et al.
Xin-Yu Li et al.
Published Erratum
The journal of headache and pain. 2023 Nov 22;24(1):156. DOI:10.1186/s10194-023-01693-z 2023
Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial [0.03%]
一项随机对照试验的延伸研究：对于之前接受预防性治疗失败的偏头痛患者而言，长期使用Eptinezumab的效果如何？
Messoud Ashina,Stewart J Tepper,Astrid Gendolla et al.
Messoud Ashina et al.
Background: Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population h...
Randomized Controlled Trial
The journal of headache and pain. 2023 Nov 20;24(1):155. DOI:10.1186/s10194-023-01688-w 2023